IMMX
Immix Biopharma Inc.
$9.09
$0.00(0.00%)
55
Overall
60
Value
50
Tech
--
Quality
Market Cap
$47.13M
Volume
855.82K
52W Range
$1.34 - $11.61
Target Price
$18.25
Company Overview
| Mkt Cap | $47.13M | Price | $9.09 |
| Volume | 855.82K | Change | +0.00% |
| P/E Ratio | -2.2 | Open | $8.52 |
| Revenue | -- | Prev Close | $9.09 |
| Net Income | $-21.6M | 52W Range | $1.34 - $11.61 |
| Div Yield | N/A | Target | $18.25 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About Immix Biopharma Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Latest News
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
TipRanks Auto-Generated Newsdesk•9 days ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Brian Anderson•12 days ago
Immix Biopharma Amends ATM Offering to Raise Capital
TipRanks Auto-Generated Newsdesk•14 days ago
Immix Biopharma Amends ATM Offering to Raise Capital
TipRanks Auto-Generated Newsdesk•14 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMMX | $9.09 | 0% | 855.82K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |